Open-label undersøgelse til evaluering af sikkerheden og effektiviteten af CABA-201 hos forsøgspersoner med aktiv idiopatisk inflammatorisk myopati
En fase 1/2, åben-label undersøgelse til evaluering af sikkerheden og effektiviteten af autologe CD19-specifikke kimære antigenreceptor-T-celler (CABA-201) hos forsøgspersoner med aktiv idiopatisk inflammatorisk myopati
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Cabaletta Bio
- Telefonnummer: 4444 267-759-3100
- E-mail: clinicaltrials@cabalettabio.com
Studiesteder
-
-
-
London, Det Forenede Kongerige, WC1N 3BG
- Rekruttering
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
Kontakt:
- Dr. Pedro Machado, FRCP, PhD
- Telefonnummer: 020 3456 7890
- E-mail: uclh.car-ttrials@nhs.net
-
Ledende efterforsker:
- Dr. Pedro Machado, FRCP, PhD
-
London, Det Forenede Kongerige, SE5 9RS
- Rekruttering
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
Kontakt:
- Rheumatology Research Team
- Telefonnummer: 0628 0207 848 0214
- E-mail: Kch-tr.CRDresearch@nhs.net
-
Ledende efterforsker:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, Det Forenede Kongerige, WC1N 3JH
- Rekruttering
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
Kontakt:
- Professor Despina Eleftheriou
- Telefonnummer: 020 7405 9200
- E-mail: Despina.Eleftheriou@gosh.nhs.uk
-
Ledende efterforsker:
- Professor Despina Eleftheriou
-
Manchester, Det Forenede Kongerige, M13 9WL
- Rekruttering
- Manchester Royal Infirmary - Accepting Adult Patients
-
Kontakt:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- Telefonnummer: 01612765052
- E-mail: Eleni.Tholouli@mft.nhs.uk
-
Ledende efterforsker:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, Det Forenede Kongerige, M6 8HD
- Rekruttering
- Salford Royal Hospital - Accepting Adult Patients
-
Kontakt:
- Michelle Beswick
- Telefonnummer: 07759 136787
- E-mail: Rheumatology.Research@nca.nhs.uk
-
Ledende efterforsker:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
-
-
California
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- University of California Irvine - Accepting Adult Patients
-
Ledende efterforsker:
- Tahseen Mozaffar, MD
-
Kontakt:
- Alpha Clinic
- Telefonnummer: 949-824-3990
- E-mail: alphaclinic@uci.edu
-
San Francisco, California, Forenede Stater, 94158
- Rekruttering
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Zilan Zheng
- Telefonnummer: 415-353-1301
- E-mail: Zilan.Zheng@ucsf.edu
-
Ledende efterforsker:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80046
- Rekruttering
- Children's Hospital Colorado - Accepting Juvenile Patients
-
Ledende efterforsker:
- Dr. Kentaro Yomogida, MD
-
Kontakt:
- Callie Strini - Primary Clinical Research Coordinator
- Telefonnummer: 720-777-9845
- E-mail: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Rekruttering
- Mayo Clinic Florida - Accepting Adult Patients
-
Kontakt:
- Gabrielle Pariseau
- Telefonnummer: 904-953-5549
- E-mail: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, Forenede Stater, 33701
- Rekruttering
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
Ledende efterforsker:
- Natalie Booth, DO
-
Kontakt:
- Laura Escobar
- Telefonnummer: 727-767-2946
- E-mail: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30032
- Rekruttering
- Emory University - Accepting Adult Patients
-
Kontakt:
- John Varghese
- E-mail: john.varghese@emory.edu
-
Ledende efterforsker:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, Forenede Stater, 30029
- Rekruttering
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
Ledende efterforsker:
- Shanmuganathan Chandrakasan, MD
-
Kontakt:
- Judson Russell
- Telefonnummer: 404-785-7263
- E-mail: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern Memorial Hospital - Accepting Adult Patients
-
Ledende efterforsker:
- Dr. George Georges, MD
-
Kontakt:
- Kaitlin King
- Telefonnummer: 312-695-0990
- E-mail: autoimmunesct@nm.org
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
Ledende efterforsker:
- Dr. Iazsmin Ventura, MD
-
Kontakt:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- Telefonnummer: 773-702-6619
- E-mail: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
Underforsker:
- Dr. Cuoghi Edens, MD, FAAP
-
Kontakt:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- E-mail: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Tyler Sorensen
- Telefonnummer: 312-277-6828
- E-mail: tsorensen@luriechildrens.org
-
Ledende efterforsker:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- University of Kansas Medical Center - Accepting Adult Patients
-
Kontakt:
- Samantha Colgan
- Telefonnummer: 913-945-9938
- E-mail: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, Forenede Stater, 20892
- Rekruttering
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
Kontakt:
- Julie Thompson
- Telefonnummer: 301-480-3191
- E-mail: Julie.thompson@nih.gov
-
Ledende efterforsker:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
Ledende efterforsker:
- Susan Prockop, MD
-
Kontakt:
- Kyle McBrearty
- Telefonnummer: 617-355-2780
- E-mail: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48105
- Rekruttering
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Abigail Whalen
- Telefonnummer: 734-615-4466
- E-mail: abigaiwh@med.umich.edu
-
Ledende efterforsker:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55902
- Rekruttering
- Mayo Clinic - Accepting Adult Patients
-
Kontakt:
- Bridget Neja
- Telefonnummer: 507-266-9150
- E-mail: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
Kontakt:
- Janvi Bhatia
- Telefonnummer: 212-774-2123
- E-mail: bhatiaj@hss.edu
-
Ledende efterforsker:
- David R. Fernandez, MD, PhD
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
Ledende efterforsker:
- Jae Park, MD
-
Kontakt:
- Atifah Osrat
- Telefonnummer: 646-608-2091
- E-mail: osrata1@mskcc.org
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Emily Gillies
- Telefonnummer: 718-696-2402
- E-mail: egillies@montefiore.org
-
Ledende efterforsker:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- Rekruttering
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
Ledende efterforsker:
- Saira Sheikh, MD
-
Kontakt:
- Leah Luizza
- E-mail: leah.luizza@med.unc.edu
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
Ledende efterforsker:
- Kaveh Ardalan, MD, MS
-
Kontakt:
- Lynn Rodgers, MS
- Telefonnummer: 919-668-2953
- E-mail: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health & Science University - Accepting Adult Patients
-
Kontakt:
- Katie Lewis
- Telefonnummer: 503-908-9724
- E-mail: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- CARTintake@chop.edu
- E-mail: CARTintake@chop.edu
-
Ledende efterforsker:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, Forenede Stater, 15261
- Rekruttering
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
Kontakt:
- Carol Oriss
- E-mail: orissca@upmc.edu
-
Ledende efterforsker:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
Kontakt:
- Vibha Chauhan, PhD
- Telefonnummer: 412-692-7924
- E-mail: Vibha.chauhan@chp.edu
-
Ledende efterforsker:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Vanderbilt University Medical Center - Accepting Adult Patients
-
Kontakt:
- Tofi Soneye
- Telefonnummer: 817-883-4730
- E-mail: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
Ledende efterforsker:
- Samuel John, MD
-
Kontakt:
- Dr. Samuel John
- E-mail: dtpteam@childrens.com
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Methodist Hospital - Accepting Adult Patients
-
Kontakt:
- Amelia A. Nounes, MSN, RN, CCRP
- Telefonnummer: 346-356-3639
- E-mail: aanounes@houstonmethodist.org
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
Ledende efterforsker:
- Huifang (Linda) Lu, MD
-
Kontakt:
- Christina Amos Briggs, BSN, RN
- Telefonnummer: 713-563-5076
- E-mail: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84113
- Rekruttering
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
Kontakt:
- Morgan Badgley - Research Coordinator
- Telefonnummer: 801-662-4812
- E-mail: morgan.badgley@hsc.utah.edu
-
Ledende efterforsker:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
Kontakt:
- Dr. Susan Shenoi, MD, MS
- Telefonnummer: 206-987-2193
- E-mail: susan.shenoi@SeattleChildrens.org
-
Ledende efterforsker:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Ikke rekrutterer endnu
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
Ledende efterforsker:
- Sara Sabbagh, DO
-
Kontakt:
- Erin Hammelev - Research Coordinator
- Telefonnummer: 414-337-7064
- E-mail: ehammele@mcw.edu
-
-
-
-
-
Roma, Italien, 00165
- Rekruttering
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Dr. Marco Becilli
- Telefonnummer: +39 0668592739
- E-mail: marco.becilli@opbg.net
-
Ledende efterforsker:
- Professor Franco Locatelli
-
-
-
-
-
Göttingen, Tyskland, 37075
- Ikke rekrutterer endnu
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
Kontakt:
- Dr. Jana Zschüntzsch
- E-mail: j.zschuentzsch@med.uni-goettingen.de
-
Ledende efterforsker:
- Dr. Jana Zschüntzsch
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andre navne:
|
|
Eksperimentel: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andre navne:
|
|
Eksperimentel: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
Tidsramme: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
Tidsramme: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
Tidsramme: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studiestol: Medical Director, Cabaletta Bio
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Muskuloskeletale sygdomme
- Sygdomme i nervesystemet
- Muskelsygdomme
- Neuromuskulære sygdomme
- Bindevævssygdomme
- Sygdomme i immunsystemet
- Hudsygdomme
- Polymyositis
- Hud- og bindevævssygdomme
- Autoimmune sygdomme
- Dermatomyositis
- Myositis
- Organiske kemikalier
- Kulbrinter
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Kulbrinter, halogeneret
- Phosphoramider
- Organophosphorforbindelser
- Cyclofosfamid
- fludarabin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CAB-201-002
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .